Qiagen N.V. (QGEN)

Market Cap	10.53B +3.0%
Revenue (ttm)	2.09B +5.7%
Net Income	424.88M +408.3%
EPS	2.04 +409.8%
Shares Out	206.07M
PE Ratio	25.01
Forward PE	20.35
Dividend	$2.41 (4.72%)
Ex-Dividend Date	Jan 8, 2026

Volume	2,253,172
Open	50.54
Previous Close	50.78
Day's Range	50.54 - 51.71
52-Week Range	39.61 - 57.82
Beta	0.68
Analysts	Buy
Price Target	51.30 (+0.43%)
Earnings Date	Feb 4, 2026

About QGEN

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights in the Netherlands and internationally. The company offers primary sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, such as kits and components for purification of nucleic acids; and...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jun 28, 1996
• Employees: 5,967
• Stock Exchange: NYSE
• Ticker Symbol: QGEN
• Website: https://www.qiagen.com

Financial Performance

In 2025, Qiagen's revenue was $2.09 billion, an increase of 5.65% compared to the previous year's $1.98 billion. Earnings were $424.88 million, an increase of 408.28%.

Analyst Summary

According to 9 analysts, the average rating for QGEN stock is "Buy." The 12-month stock price target is $51.3, which is an increase of 0.43% from the latest price.

Price Target

$51.3

(0.43% upside)

Analyst Consensus: Buy